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A Standard for Low Molecular Weight Heparin?
In the last few years many articles on low-
molecular-weight heparins (LMWH) ap-
peared in this journal, both in regular issues
and in supplements. It is therefore not sur-
prising that in the present issue a discussion
appears between Drs. Johnson and Fareed
on the use of a standard preparation for the
comparison of the activities of low molecu-
lar weight heparins. The discussion was pro-
voked by two articles from Dr. Fareed's lab-
oratory published in a supplement for Hae-
mostasis ll,2l.
It is a pity that these articles contain more
than the inevitable number of typesetting
errors. I do feel that, as a main editor, I owe
our readers an apology here. The careless
presentation is all the more regrettable be-
cause it tends to distract the reader from the
main issue: Is there a need for a LMWH
standard? Can a useful standard be pre-
sented at this moment? or rather, What is the
use of a standard such as it can be presented
at this moment?
The frrst question must be answered in
the affrrmative. There is an obvious need for
order in this field where 12 or more different
preparations are assessed according to at
least three different measuring principles,
that moreover are applied in an uncounted
number of different wavs.
The second question, Can a useful stan-
dard be presented at this time?, requires
some caution. It is at the very heart of the
matter that properties that are tightly linked
in unfractionated heparin are separated in
LMWH. The two properties that everybody
wants to see dissociated are antithrombotic
efficiency and induction of a bleeding ten-
dency. The two that everybody knows to be
separated are antifactor Xa and antithrom-
bin activity. The latter are not the only prop-
erties ofheparins and they are surely not the
respective indicators of therapeutic effi-
ciency and tendency to bleeding, although
this for some time has been a common hope
of those interested in the freld. In different
preparations antithrombin and anti-Xa ac-
tivity are separated to a different extent, the
extremes being Choay's pentasaccharide [3]
that has virtually no antithrombin activity
whereas some heparinoids may have no anti-
Xa activity and a persistent antithrombin
activity. Anyhow, it is common knowledge
that within the group of LMWH, unlike be-
tween unfractionated heparins, the ratio of
the two activities varies considerably. It
means that any LMWH when compared to
any standard will exhibit an activity that is
dependent upon the property tested. Of
course the people responsible for the estab-
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lishment of the NIBSC standard are com-
pletely aware of this, and that is why they
standardize on well-defrned properties such
as the antifactor Xa activity. It is the gist of
the Fareed articles that they show that apart
from antithrombin and anti-Xa activities
several other properties of LMWH vary in-
dependently in different preparations, as
was quite reasonable to suspect.
It is essentially unknown which of the
properties of heparin is (are) the pharmaco-
logically important one(s). There is good rea-
son to assume that it is notthe anti-Xa activity
because it has been shown that in plasma,
acting on endogenously activated factors, un-
fractionated heparin, which cannot be denied
antithrombotic activity, has no antiprothrom-
binase action to speak of [4, 5]. As factor Xa is
the active site carrier in prothrornbinase, this
means that in plasma and therefore in all
probability, in vivo, the anti-factor Xa action
is of no key pharmacological importance.
Several perfectly effrcient LMWH show
hardly any antiprothrombinase activity in
plasma either. Only in a drug such as Choay's
pentasaccharide can the antiprothrombinase
(i.e. the physiological anti-Xa) action be
shown to be of importance in plasma. In that
case the inhibition of prothrombinase leads
to a secondary inhibition of thrombin by
inhibiting its generation and not by increas-
ing its scavenging. The fact that the penta-
saccharide has been shown to be (mildly)
antithrombotic in animals [6] therefore does
not prooye that anti-Xa action is pharmaco-
logically important. Anti-Xa action always
implies lower effective thrombin production,
whereas the reverse is not true.
Those who are going to use the new hepa-
rins in practice, i.e. clinicians, are not inter-
ested in the technical discussion on the
mechanism of action of the laboratory tests.
They want a frgure that indicates the effrcacy
of antithrombotic treatment and a figure,
preferably a different one, on the risk of
bleeding.
From the above it is clear that the anti-Xa
action is not likely to be useful as such a clin-
ical parameter, especially in drugs like the
LMWH where it is dissociated from other
heparin properties. The antithrombin activ-
ity presents itselfas an alternative. It is by no
means sure that this is the pharmacologically
important property either. There are many
other actions of heparin that might in fact
cause or influence the pharmacological ac-
tivity of heparin. One might cite its inducing
a tissue-factor VIIa inhibitor, its action on
endothelial cells or platelets, its action on
blood lipids, its action on fibrinolysis, etc.
Personally, I nevertheless have a ten-
dency to reserve an important place for anti-
thrombin action, be it only because it is the
only known action of heparins that causes
the same net effect (i.e. less thrombin) as
another potent antithrombotic: oral antico-
agulation.
Even though pharmacologically irrele-
vant, the anti-Xa action has one important
advantage: it is very convenient to measure.
In fact, it is often the only parameter that
appears to change in the plasma of patients
treated with LMWH. At its very best, how-
ever, this must be considered an epiphenom-
enon that changes together with the pharma-
cologically important property whatever that
may be.
It is the very nature offractionated hepa-
rin that, unlike unfractionated heparin, there
are important shifts in the ratio of the differ-
ent activities. No matter what the clinically
important parameter may be, the ratio of its
activity to any other measured activity must
be assumed to vary from one LMWH prepa-
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ration to another. For each separate prepara-
tion the anti-factor Xa activity may be a con-
venient means to get an impression of the
variations in the level of the pharmacologi-
cally important activity. For between-prepa-
ration comparison it is ipso facto useless.
' Therefore. the anti-factor Xa-based com-
parison of a LMWH to a standard may be
useful for the standardization of laboratory
procedures but is no rational way to arrive at
clinical comparability. This may be obvious
to the specialist but it must be stressed in
order not to induce a false sense of security
among nonspecialized clinicians.
In order to develop the argument further
it may be useful to recall the importance of
platelet factor 4 (pf4) neutralization ofhep-
ann.
In ideally prepared platelet-free plasma,
such as is of course used by all those wishing
to assess heparin levels (blood collected in
platelet-inhibiting cocktail, first centrifuga-
tion at 15 oC, etc.) pf 4 does not play a role.
In less ideally prepared plasma it will neu-
tralize 0.05 - 0.25Ulml of unfractionated
heparin [7].
In vivo, and especially at the site of a
thrombus, platelets shed pf 4 and neutralize
heparin. Unfractionated heparin is very effr-
ciently suppressed, LMWHs are less subject
to this inactivation and to a different extent.
The presence of (low-affinity) fractions with
no or hardly any anti-Ila or anti-Xa actiyity
of their own but that do bind to pf 4 may
greatly modify the action of a LMWH in
platelet-rich plasma and presumably in
vivo.
Such differences would not be recognized
by comparison of anti-Xa actions in platelet-
poor plasma. Again the comparison of an
unknown LMWH with the standard would
fall short ofclinical reality.
In my opinion the following consider-
ations are essential for the reproducible
characterization of a heparin preparation:
(l) It should be recognized that every hep-
arin preparation has different activities that
may contribute to its pharmacological effi-
cacy in a different way. Probably the anti-
thrombin activity and pf 4 susceptibility are
important. The importance of anti-factor Xa
activity can, on good grounds, be supposed
to be minor.
(2) The behavior towards (AT III) heparin
of activated clotting factors generated in
clotting plasma is different from that of iso-
lated clotting factors, even if the latter are
added to plasma [5]. Tests based on the inac-
tivation of added isolated factors should
therefore be interpreted with caution.
(3) Comparing one single property of a
LMWH fraction to a single property of a
standard preparation may induce a false
sense of security especially among the non-
specialists that are going to use the prepara-
tions in medical practice.
These considerations should not deter
from establishing adequate standardization
for the characterization of LMWH, but
rather favor standardization that meets the
requirements that can be foreseen on the
basis of the present state of the art. That is,
each heparin preparation should be charac-
terized for its antithrombin activity, its pf 4
susceptibility and - for those who take a
fancy to it - its anti-factor Xa activity. For
clinical use it might be the best policy to
indicate the strength of a LMWH on the
basis of a property that is easy to measure
and does not suggest understanding of the
system beyond our present knowledge, i.e.
weight per volume. Up to this moment one
cannot blame the FDA and the German
Government to adopt this position.
Editorial
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